Financing, Equity Capital Markets

Immunovant, Inc.

09/23
|
$322.0 Million
Immunovant
Piper Sandler served as bookrunner for Immunovant, Inc. on a follow-on offering and PIPE offering
Sub-Type
Follow-On Offering
Sub-Sector
Biopharma